Concord Wealth Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Concord Wealth Partners's BIIB Position: Q2 2026 in Review
Concord Wealth Partners opened a new position in Biogen (BIIB) in Q2 2026: 114 shares worth $24.6K. The stake represents ﹤0.01% of the portfolio and ranks #453 among its holdings. This is a return to the name: Concord Wealth Partners previously reported a position in BIIB as recently as Q4 2025.
Concord Wealth Partners first reported a position in BIIB in Q4 2020 and has held it in 21 quarters since. The position peaked at $196K in Q4 2023. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Concord Wealth Partners held 114 shares of Biogen worth $24.6K as of Q2 2026.
- Biogen was a new Concord Wealth Partners position in Q2 2026.
- Biogen made up ﹤0.01% of Concord Wealth Partners's portfolio in Q2 2026, its #453 holding.
- Concord Wealth Partners first reported a position in Biogen in Q4 2020 and has held it in 21 quarters since.
- Concord Wealth Partners's Biogen position peaked at $196K in Q4 2023.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Concord Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.